共 45 条
- [21] Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) - CheckMate 714ANNALS OF ONCOLOGY, 2016, 27Haddad, R.Gillison, M.Ferris, R. L.Harrington, K.Monga, M.Baudelet, C.Geese, W. J.Argiris, A.
- [22] Maintenance therapy with regorafenib (REGO) versus placebo after first-line (1L) platinum and fluoropyrimidinesbased chemotherapy in HER2-negative advanced gastric (GC)/gastroesophageal junction (GEJ) cancer: Results of phase II randomized a-MANTRA study (GOIRC-05-2016)ANNALS OF ONCOLOGY, 2024, 35 : S171 - S171Damato, A.Bilancia, D.Iachetta, F.Strippoli, A.Filiali, F.Casaretti, R.Bernardini, I.Bellotti, G.Frassineti, G. L.Di Fabio, F.Aieta, M.Ghidini, M.Trentin, C.Cardellino, G.Gervasi, E.Romagnani, A.Cinieri, S.Normanno, N.Boni, L.Pinto, C.
- [23] A phase Ib/II, multicenter, open-label study of AK104, a PD-1/CTLA-4 bispecific antibody, combined with chemotherapy (chemo) as first-line therapy for advanced gastric (G) or gastroesophageal junction (GEJ) cancer: 2-Year update dataJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Ji, JiafuShen, LinLi, ZiyuGao, XiangyuJi, KeChen, YeXu, NongLiu, TianshuYang, NongZhong, HaijunLi, ChangzhengGuo, ZengqingFan, QingxiaLin, XiaoyanYao, ZhifangLiu, WeiWang, Zhongmin MaxwellLi, BaiyongXia, Yu
- [24] Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patients with metastatic colorectal cancer (mCRC).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)Hurwitz, HerbertTan, Benjamin R.Reeves, James AndrewXiong, Henry Q.Somer, Bradley G.Lenz, Heinz-JosefHochster, Howard S.Scappaticci, FrankPalma, John F.Mancao, ChristophLee, John J.Nicholas, AlanSommer, NicolasBendell, Johanna C.
- [25] Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)Zatloukal, P.Heo, D. S.Park, K.Kang, J.Butts, C.Bradford, D.Graziano, S.Huang, B.Healey, D.
- [26] Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab plus chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 372 - 372Shitara, KoheiPophale, RupeshMatsangou, MariaPark, Jung WookOh, MokBhattacharya, Pranob P.Ranganath, Radhika
- [27] Zolbetuximab+mFOLFOX6 as First-Line (1L) treatment for patients (Pts) with Claudin-18.2+(CLDN18.2+) / HER2-Locally Advanced (LA) unresectable or metastatic Gastric or Gastroesophageal Junction (mG/GEJ) adenocarcinoma: primary results from Phase 3 SPOTLIGHT StudyONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 115 - 116Lordick, F.Shitara, K.Bang, Y. -JEnzinger, P.Ilson, D.Shah, M. A.Van Cutsem, E.Xu, R. -HAprile, G.Xu, J.Chao, J.Pazo-Cid, R.Kang, Y. K.Yang, J.Moran, D.Bhattacharya, P.Arozullah, A.Park, J. W.Ajani, J.
- [28] Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18.2+) / HER22 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT studyJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : LBA292 - LBA292Shitara, KoheiLordick, FlorianBang, Yung-JueEnzinger, Peter C.Ilson, David H.Shah, Manish A.Van Cutsem, EricXu, Rui-huaAprile, GiuseppeXu, JianmingChao, JosephPazo-Cid, RobertoKang, Yoon-KooYang, JianningMoran, Diarmuid MartinBhattacharya, Pranob P.Arozullah, AhsanPark, Jung WookAjani, Jaffer A.
- [29] HELOISE: phase IIIB randomized multicenter study comparing two trastuzumab (H) dose regimens combined with chemotherapy (CT) as first-line (1L) therapy in patients (pts) with HER2-positive metastatic gastric/gastroesophageal junction adenocarcinoma (mGC/GEJC)CANCER RESEARCH, 2016, 76Shah, Manish A.Xu, RuihuaBang, Yung-JueHoff, Paulo M.Liu, TianshuHerraez-Baranda, Luis A.Xia, FanGarg, AmitShing, MonaTabernero, Josep
- [30] Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinomaANNALS OF ONCOLOGY, 2023, 34 : S1322 - S1322Ajani, J. A.Lordick, F.Bang, Y-J.Enzinger, P. C.Ilson, D. H.Shah, M. A.Van Cutsem, E.Xu, R-H.Aprile, G.Xu, J.Cid, R. A. PazoKang, Y-K.Yang, J.Moran, D.Bhattacharya, P.Matsangou, M.Arozullah, A.Park, J. W.Shitara, K.